Asset Details
Do you wish to reserve the book?
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
Do you wish to request the book?
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
2019
Overview
Biologics and apremilast have advanced psoriasis management by adding treatment options. This study evaluated persistence, adherence and healthcare costs among biologic-naive patients receiving apremilast or biologics.
Administrative claims data for adults starting apremilast or biologics from 1 January 2013 to 30 June 2016 were matched based on demographics.
Apremilast (n = 703) and biologics (n = 1378) had similar baseline characteristics. 12-month persistence and adherence rates were similar. Adjusted total healthcare costs were lower with apremilast versus biologics (p < 0.001) due to lower total outpatient pharmacy costs (p < 0.001).
Real-world apremilast users had similar adherence and lower total healthcare costs versus biologic users. Apremilast's cost advantage was evident regardless of whether the patients were persistent or nonpersistent, or switched or did not switch treatments.
Publisher
Future Medicine Ltd
Subject
/ Anti-Inflammatory Agents, Non-Steroidal - economics
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Biological Products - economics
/ Biological Products - therapeutic use
/ Costs
/ Female
/ Health Care Costs - statistics & numerical data
/ Humans
/ Male
/ Patients
/ Pharmacy
/ Thalidomide - analogs & derivatives
